特应性皮炎治疗药物应用管理专家共识（2024版）

doi:10.35541/cjd.20230358

Abstract

Abstract: 【Abstract】 Atopic dermatitis is a common chronic recurrent inflammatory skin disease. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants and glucocorticoids, etc. In recent years, biologics and a variety of small-molecule drugs have been approved for the treatment of atopic dermatitis. Based on recent research progress, Chinese and international guidelines or consensus, and experts′ clinical experience, China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, and National Clinical Research Center for Dermatologic and Immunologic Diseases convened experts to develop this consensus on strategies for the clinical application of therapeutic drugs for atopic dermatitis, monitoring and management of adverse drug reactions, and drug management in special populations, aiming to provide a reference for the application and management of therapeutic drugs for atopic dermatitis.

Key words: Dermatitis, atopic, Medication therapy management, Biological agents, Molecular targeted therapy, Drug toxicity, Special population, Expert consensus

China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024）[J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.doi:10.35541/cjd.20230358

References ［69］

［1］	Yamamura K, Nakahara T. The dawn of a New Era in atopic dermatitis treatment［J］. J Clin Med, 2022,11（20）:6145. doi: 10.3390/jcm11206145.
［2］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［3］	Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema［J］. BMJ, 2007,334（7606）:1272. doi: 10.1136/bmj.39195.636319.80.
［4］	Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021［J］. J Dermatol, 2022,49（10）:e315⁃e375. doi: 10.1111/1346⁃8138.16527.
［5］	Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies［J］. J Am Acad Dermatol, 2014,71（1）:116⁃132. doi: 10.1016/j.jaad. 2014.03.023.
［6］	Butala S, Paller AS. Optimizing topical management of atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2022,128（5）:488⁃504. doi: 10.1016/j.anai.2022.03.004.
［7］	Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids［J］. J Am Acad Dermatol, 2006,54（1）:1⁃15; quiz 16⁃18. doi: 10.1016/j.jaad.2005.01.010.
［8］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ partⅡ: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. doi: 10.1111/jdv.18429.
［9］	Chi CC, Kirtschig G, Aberer W, et al. Updated evidence⁃based （S2e） European Dermatology Forum guideline on topical corticosteroids in pregnancy［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:761⁃773. doi: 10.1111/jdv.14101.
［10］	Chi CC, Wang SH, Mayon⁃White R, et al. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population⁃based cohort study［J］. JAMA Dermatol, 2013,149（11）:1274⁃1280. doi: 10.1001/jamadermatol.2013.5768.
［11］	Sathishkumar D, Moss C. Topical therapy in atopic dermatitis in children［J］. Indian J Dermatol, 2016,61（6）:656⁃661. doi: 10.4103/0019⁃5154.193677.
［12］	Howell AN, Ghamrawi RI, Strowd LC, et al. Pharmacological management of atopic dermatitis in the elderly［J］. Expert Opin Pharmacother, 2020,21（7）:761⁃771. doi: 10.1080/14656566.2020. 1729738.
［13］	Remitz A, De Pità O, Mota A, et al. Position statement: topical calcineurin inhibitors in atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2018,32（12）:2074⁃2082. doi: 10.1111/jdv. 15272.
［14］	Lam M, Zhu JW, Tadrous M, et al. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2021,157（5）:549⁃558. doi: 10.1001/jamadermatol.2021.0345.
［15］	Paller AS, Fölster⁃Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis［J］. J Am Acad Dermatol, 2020,83（2）:375⁃381. doi: 10.1016/j.jaad.2020.03.075.
［16］	Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1644⁃1659. doi: 10.1111/jdv.15709.
［17］	Salava A, Perälä M, Pelkonen A, et al. Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36⁃month follow⁃up study［J］. Clin Exp Dermatol, 2022,47（5）:889⁃902. doi: 10.1111/ced.15024.
［18］	Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double⁃blind, vehicle⁃controlled study in healthy volunteers［J］. Am J Clin Dermatol, 2016,17（5）:519⁃526. doi: 10.1007/s40257⁃016⁃0204⁃6.
［19］	Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（5）:585⁃593. doi: 10.1001/jamadermatol.2019. 0008.
［20］	McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis［J］. J Pharm Technol, 2019,35（4）:172⁃178. doi: 10.1177/8755122519844507.
［21］	Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and a subsequent open⁃label, long⁃term study［J］. J Am Acad Dermatol, 2021,85（4）:854⁃862. doi: 10.1016/j.jaad.2021.06.014.
［22］	Hur MS, Choe YB, Ahn KJ, et al. Synergistic effect of H1⁃antihistamines on topical corticosteroids for pruritus in atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Dermatol, 2019,31（4）:420⁃425. doi: 10.5021/ad.2019.31.4.420.
［23］	Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: partⅠ. Pregnancy［J］. J Am Acad Dermatol, 2014,70（3）:401.e1⁃14; quiz 415. doi: 10.1016/j.jaad.2013.09.010.
［24］	Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema ⁃ a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2007,21（5）:606⁃619. doi: 10.1111/j.1468⁃3083.2006.02023.x.
［25］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: partⅡ［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv.14888.
［26］	Altomare G, Ayala F, Bardazzi F, et al. Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference［J］. G Ital Dermatol Venereol, 2014,149（5）:607⁃625.
［27］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema: partⅠ ⁃ systemic therapy［J］. J Eur Acad Dermatol Venereol, 2022,36（9）:1409⁃1431. doi: 10.1111/jdv.18345.
［28］	Tanei R. Atopic dermatitis in older adults: a review of treatment options［J］. Drugs Aging, 2020,37（3）:149⁃160. doi: 10.1007/s40266⁃020⁃00750⁃5.
［29］	Lee JH, Kim JE, Park GH, et al. Consensus update for systemic treatment of atopic dermatitis［J］. Ann Dermatol, 2021,33（6）:497⁃514. doi: 10.5021/ad.2021.33.6.497.
［30］	Drucker AM, Eyerich K, de Bruin⁃Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement［J］. Br J Dermatol, 2018,178（3）:768⁃775. doi: 10.1111/bjd.15928.
［31］	Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis［J］. J Am Acad Dermatol, 2018,78（4）:733⁃740.e11. doi: 10.1016/j.jaad.2017.09.074.
［32］	Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate⁃to⁃severe atopic dermatitis: a systematic review and meta⁃analysis［J］. J Dermatol Sci, 2018,90（2）:190⁃198. doi: 10.1016/j.jdermsci.2018.01.016.
［33］	de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phaseⅢ clinical trial （LIBERTY AD CAFÉ）［J］. Br J Dermatol, 2018,178（5）:1083⁃1101. doi: 10.1111/bjd.16156.
［34］	Matsutani M, Imai Y, Inoue Y, et al. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real⁃world clinical practice［J］. J Dermatol, 2021,48（10）:1564⁃1568. doi: 10.1111/1346⁃8138.16039.
［35］	Rossi M, Rovati C, Arisi M, et al. A short cycle of narrow⁃band UVB phototherapy in the early phase of dupilumab therapy can provide a quicker improvement of severe atopic dermatitis［J］. Dermatology, 2021,237（3）:407⁃415. doi: 10.1159/000512456.
［36］	Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open⁃Label Study of Adults with Moderate⁃to⁃Severe Atopic Dermatitis［J］. Am J Clin Dermatol, 2022,23（3）:393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0.
［37］	Neagu N, Dianzani C, Avallone G, et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2022,36（6）:820⁃835. doi: 10. 1111/jdv.17981.
［38］	Papp KA, Hong CH, Lansang MP, et al. Practical management of patients with atopic dermatitis on dupilumab［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1805⁃1828. doi: 10.1007/s13555⁃021⁃00586⁃w.
［39］	Guex⁃Crosier Y, Di⁃Lucca J, Häusermann P, et al. Management of dupilumab⁃associated ocular surface diseases in atopic dermatitis patients［J］. Swiss Med Wkly, 2021,151:w30020. doi: 10.4414/SMW.2021.w30020.
［40］	薛璐, 王惠平, 李燕. 度普利尤单抗治疗特应性皮炎引起"度普利尤单抗面部红斑"1例［J］. 中华皮肤科杂志, 2022,55（4）:337⁃338. doi: 10.35541/cjd.20210453.
［41］	Muzumdar S, Skudalski L, Sharp K, et al. Dupilumab facial redness/dupilumab facial dermatitis: a guide for clinicians［J］. Am J Clin Dermatol, 2022,23（1）:61⁃67. doi: 10.1007/s40257⁃021⁃00646⁃z.
［42］	Pope EM, Laageide L, Beck LA. Management of allergic skin disorders in pregnancy［J］. Immunol Allergy Clin North Am, 2023,43（1）:117⁃132. doi: 10.1016/j.iac.2022.05.012.
［43］	Koskeridis F, Evangelou E, Ntzani EE, et al. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta⁃analysis［J］. J Cutan Med Surg, 2022,26（6）:613⁃621. doi: 10.1177/12034754221130969.
［44］	Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine⁃induced immunity: a randomized, placebo⁃controlled trial in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Am Acad Dermatol, 2019,80（1）:158⁃167.e1. doi: 10.1016/j.jaad.2018.07.048.
［45］	Zhao DJ, Huang LM, Xiao J, et al. Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: a systematic review and meta⁃analysis of randomized controlled trials［J］. Medicine （Baltimore）, 2023,102（31）:e34516. doi: 10.1097/MD. 0000000000034516.
［46］	Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate⁃to⁃severe atopic dermatitis: pooled analysis of five randomized, double⁃blind, placebo⁃controlled phaseⅡ and phaseⅢ trials［J］. Br J Dermatol, 2022,187（6）:888⁃899. doi: 10.1111/bjd.21867.
［47］	Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. doi: 10.1016/S0140⁃6736（21）00588⁃2.
［48］	Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow⁃up data from the measure up 1 and measure up 2 randomized clinical trials［J］. JAMA Dermatol, 2022,158（4）:404⁃413. doi: 10.1001/jamadermatol.2022.0029.
［49］	Meher BR, Mohanty RR, Padhy BM. Efficacy and safety of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis: a meta⁃analysis of randomized clinical trials［J］. J Dermatolog Treat, 2022,33（4）:2335⁃2343. doi: 10.1080/09546634. 2021.1961997.
［50］	Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036.
［51］	Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis from the phaseⅡ and phase Ⅲ clinical trial program［J］. Am J Clin Dermatol, 2021,22（5）:693⁃707. doi: 10. 1007/s40257⁃021⁃00618⁃3.
［52］	Gooderham MJ, Pink AE, Simpson EL, et al. Abrocitinib 100 mg once daily for moderate⁃to⁃severe atopic dermatitis: a review of efficacy and safety, and expert opinion on use in clinical practice［J］. Dermatol Ther （Heidelb）, 2023,13（9）:1893⁃1907. doi: 10. 1007/s13555⁃023⁃00948⁃6.
［53］	Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors［J］. Expert Rev Clin Immunol, 2022,18（5）:439⁃459. doi: 10.1080/1744666X.2022. 2060822.
［54］	Clarke B, Yates M, Adas M, et al. The safety of JAK⁃1 inhibitors［J］. Rheumatology （Oxford）, 2021,60（Suppl 2）:ii24⁃ii30. doi: 10.1093/rheumatology/keaa895.
［55］	Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate⁃to⁃severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety （JADE） REGIMEN phase 3 trial［J］. J Am Acad Dermatol, 2022,86（1）:104⁃112. doi: 10. 1016/j.jaad.2021.05.075.
［56］	Dodson J, Lio PA. Biologics and small molecule inhibitors: an update in therapies for allergic and immunologic skin diseases［J］. Curr Allergy Asthma Rep, 2022,22（12）:183⁃193. doi: 10. 1007/s11882⁃022⁃01047⁃w.
［57］	Liu L, Luo Y, Zhou M, et al. Tripterygium agents for the treatment of atopic eczema: a bayesian analysis of randomized controlled trials［J］. Phytomedicine, 2019,59:152914. doi: 10. 1016/j.phymed.2019.152914.
［58］	周俐宏, 孙晓丽, 柳舟, 等. 口服复方甘草酸苷联合常规疗法治疗皮炎湿疹疗效及安全性的Meta分析［J］. 中国中西医结合皮肤性病学杂志, 2019,18（2）:97⁃102. doi: 10.3969/j.issn. 1672⁃0709.2019.02.001.
［59］	树叶, 刘向宇, 罗鸯鸯, 等. 白芍总苷治疗儿童特应性皮炎的临床疗效［J］. 中国医师杂志, 2021,23（12）:1881⁃1883. doi: 10.3760/cma.j.cn431274⁃20210409⁃00401.
［60］	中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志, 2023,56（1）:5⁃15. doi: 10.35541/cjd.20220618.
［61］	Carrascosa JM, de la Cueva P, de Lucas R, et al. Patient journey in atopic dermatitis: the real⁃world scenario［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1693⁃1705. doi: 10.1007/s13555⁃021⁃00592⁃y.
［62］	Boguniewicz M, Fonacier L, Guttman⁃Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape［J］. Ann Allergy Asthma Immunol, 2018,120（1）:10⁃22.e2. doi: 10.1016/j.anai.2017.10.039.
［63］	Wollenberg A, Thyssen JP, Bieber T, et al. A detailed look at the European Medicines Agency′s recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2023,37（10）:2041⁃2046. doi: 10.1111/ jdv.19255.
［64］	De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751.
［65］	申晨, 陶娟. 特应性皮炎长期控制的评估演变与达标治疗［J］. 中华皮肤科杂志, 2022,55（5）:442⁃445. doi: 10.35541/cjd. 20210680.
［66］	Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy［J］. Dermatology, 2021,237（4）:535⁃541. doi: 10.1159/000512890.
［67］	de Wijs L, Thyssen JP, Vestergaard C, et al. An approach for the transition from systemic immunosuppressants to dupilumab［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:e221⁃e223. doi: 10. 1111/jdv.16941.
［68］	Rick JW, Lio P, Atluri S, et al. Atopic dermatitis: a guide to transitioning to janus kinase inhibitors［J］. Dermatitis, 2023,34（4）:297⁃300. doi: 10.1097/DER.0000000000000950.
［69］	Saeki H, Akiyama M, Abe M, et al. English version of Japanese guidance for the use of oral Janus kinase （JAK） inhibitors in the treatments of atopic dermatitis［J］. J Dermatol, 2023,50（1）:e1⁃e19. doi: 10.1111/1346⁃8138.16635.

[1]	Chinese Society of Dermatology, China Dermatologist Association, Chinese Association of Integrative Medicine Board of Dermatovenereology. Expert consensus on the clinical application of chemical peeling in China （2024 public version） [J]. Chinese Journal of Dermatology, 2024, 0(5): 20230620-e20230620.
[2]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[3]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[4]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.
[5]	Mycobacteriosis Research Group, China " Belt and Road " Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the diagnosis and treatment of cutaneous nontuberculous mycobacterial diseases in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 109-118.
[6]	Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association. Expert consensus on human interferon α1b for the treatment of melanoma （2024） [J]. Chinese Journal of Dermatology, 2024, 57(1): 1-7.
[7]	China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717.
[8]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[9]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[10]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[11]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[12]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[13]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[14]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[15]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.

Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［69］

Related Articles 15

Metrics

Comments

Recommended 10